Media headlines about MetLife (NYSE:MET) have been trending somewhat positive on Saturday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. MetLife earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave news stories about the financial services provider an impact score of 46.0237691511095 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:
- MetLife, Inc. (MET): Stock in Featured Spotlight: (stockquote.review)
- PNB MetLife Insurance to file for IPO by August (timesofindia.indiatimes.com)
- What Prudential Has in Mind for US Workplace Solutions (finance.yahoo.com)
- BRIEF-Metlife Names Susan Greenwell As Head Of Global Government Relations (reuters.com)
- MetLife Names Susan Greenwell as Head of Global Government Relations (businesswire.com)
Shares of NYSE MET traded up $0.05 during midday trading on Friday, hitting $47.49. 4,377,761 shares of the company’s stock were exchanged, compared to its average volume of 5,506,473. The company has a current ratio of 0.15, a quick ratio of 0.15 and a debt-to-equity ratio of 0.29. The company has a market cap of $49,178.34, a PE ratio of 10.55, a P/E/G ratio of 0.84 and a beta of 1.24. MetLife has a twelve month low of $43.38 and a twelve month high of $55.91.
MET has been the subject of several research analyst reports. Atlantic Securities raised MetLife from a “neutral” rating to an “overweight” rating in a report on Monday, March 26th. UBS restated a “neutral” rating and issued a $51.00 target price (down from $52.00) on shares of MetLife in a research note on Friday, March 2nd. Keefe, Bruyette & Woods restated a “buy” rating and issued a $56.00 target price on shares of MetLife in a research note on Friday, February 23rd. Deutsche Bank started coverage on MetLife in a research note on Tuesday, January 2nd. They issued a “hold” rating and a $55.00 target price for the company. Finally, Morgan Stanley decreased their target price on MetLife from $58.00 to $56.00 and set an “equal weight” rating for the company in a research note on Thursday, April 5th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $56.75.
MetLife Company Profile
MetLife, Inc engages in the insurance, annuities, employee benefits, and asset management businesses. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and stable value products, including general and separate account guaranteed interest contracts, and private floating rate funding agreements.
Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.